Estudio de enfermedad residual axilar, tras biopsia selectiva de ganglio centinela positivo, en cáncer de mama

  1. Zaragoza Zaragoza, Carmen
Dirigida per:
  1. Manuel Díez Miralles Director/a
  2. Luis Manuel Hernández Blasco Director/a

Universitat de defensa: Universidad Miguel Hernández de Elche

Fecha de defensa: 28 de d’octubre de 2016

Tribunal:
  1. Antonio F. Compañ Rosique President/a
  2. María Dolores Balsalobre Salmerón Secretari/ària
  3. Jaime Merino Sánchez Vocal
  4. José Miguel Sempere Ortells Vocal
  5. Jaime Ruiz Tovar Vocal

Tipus: Tesi

Resum

ABSTRACT Today, sentinel lymph node dissection has replaced as standard procedure for axilla management, in patients with breast cancer whom clinically negati- ve axilla, with the same disease control and provides information for staging, avoiding morbidity. Furthermore, when the sentinel node is positive, there is a low risk of a ecting non-sentinel lymph node. However, there is controversy about which patients we can avoid the axillary lymph node dissection. Objectives: To evaluate factors related to the presence of residual disease after positive sentinel lymph node biopsy, and to validate predictive models MSKCC and Tenon in our series. Patients and Methods: In this retrospective study, we included all patients with a positive sentinel lymph node biopsy who underwent breast cancer sur- gery in our hospital in the last 10 years.. We obtained variables in relation to the patient, the tumor and the sentinel lymph node, and univariante and mul- tivariate analysis were performed to evaluate the relationship between this variables and the presence of residual disease, building a predictive model. We applied nomograms, the MSKCC and Tenon, to our population, and the area under the receiver operating characteristic curve was calculated for each of the models. Results: The variables signi cantly related with axillary metastatic spread to non-sentinel node were: The presence of macrometastases in the sentinel lymph node (especially if there are 2 or more a ected lymph nodes), the tumor size greater than 3 cm, lympho-vascular involvement, extranodal spread, the absence of negative sentinel node, and performing a mastectomy. After multi- variate analysis we could develop a predictor formula, with the last 4 features, validating it with an external group. The MSKCC and Tenon models are also validated, obtaining ROC curve values similar to our own model. Conclusions: Both, our own model and the externals, represent a useful tool in making treatment decisions in patients with breast cancer and positive sentinel node . Always as value added to other patient and disease variables.